Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo.

Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo.

Item
http://www.wikidata.org/entity/Q35152542
Activator protein 1 promotes gemcitabine‑induced apoptosis in pancreatic cancer by upregulating its downstream target BimTheaflavin-3, 3'-digallate decreases human ovarian carcinoma OVCAR-3 cell-induced angiogenesis via Akt and Notch-1 pathways, not via MAPK pathways.Celecoxib-erlotinib combination delays growth and inhibits angiogenesis in EGFR-mutated lung cancer.Combination of ruthenium(II)-arene complex [Ru(η6-p-cymene)Cl2(pta)] (RAPTA-C) and the epidermal growth factor receptor inhibitor erlotinib results in efficient angiostatic and antitumor activity.Noninvasive Bioluminescence Imaging of AKT Kinase Activity in Subcutaneous and Orthotopic NSCLC Xenografts: Correlation of AKT Activity with Tumor Growth Kinetics.JD enhances the anti-tumour effects of low-dose paclitaxel on gastric cancer MKN45 cells both in vitro and in vivo.Bevacizumab counteracts VEGF-dependent resistance to erlotinib in an EGFR-mutated NSCLC xenograft model.Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer.CD44+/CD24- phenotype predicts a poor prognosis in triple-negative breast cancer.Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes.The asphericity of the metabolic tumour volume in NSCLC: correlation with histopathology and molecular markers.HCRP1 is downregulated in non-small cell lung cancer and regulates proliferation, invasion, and drug resistance.Value of combining serum carcinoembryonic antigen and PET/CT in predicting EGFR mutation in non-small cell lung cancer.Tetrandrine suppresses lung cancer growth and induces apoptosis, potentially via the VEGF/HIF-1α/ICAM-1 signaling pathway.Erlotinib intercalating pemetrexed/cisplatin versus erlotinib alone in Chinese patients with brain metastases from lung adenocarcinoma: a prospective, non-randomised, concurrent controlled trial (NCT01578668).The antiangiogenic action of cisplatin on endothelial cells is mediated through the release of tissue inhibitor of matrix metalloproteinases-1 from lung cancer cells
P2860

Erlotinib-cisplatin combination inhibits growth and angiogenesis through c-MYC and HIF-1α in EGFR-mutated lung cancer in vitro and in vivo.

Item
http://www.wikidata.org/entity/Q35152542
description
2015 nî lūn-bûn
@nan
2015 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
name
Erlotinib-cisplatin combinatio ...... g cancer in vitro and in vivo.
@ast
Erlotinib-cisplatin combinatio ...... g cancer in vitro and in vivo.
@en
type
label
Erlotinib-cisplatin combinatio ...... g cancer in vitro and in vivo.
@ast
Erlotinib-cisplatin combinatio ...... g cancer in vitro and in vivo.
@en
prefLabel
Erlotinib-cisplatin combinatio ...... g cancer in vitro and in vivo.
@ast
Erlotinib-cisplatin combinatio ...... g cancer in vitro and in vivo.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P932
P356
P1433
P1476
Erlotinib-cisplatin combinatio ...... g cancer in vitro and in vivo.
@en
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P932